GlycoEra is leveraging its expertise in exploiting natural glycan-mediated pathways to unlock unique biological activities for therapeutic targets, using its propriety CustomGlycan platform. The company is developing first-in-class therapeutics with novel modes of action enabled by fully human, highly homogenous, and customized glycan structures assembled onto glycoproteins in a site-specific manner.
The glycobiology and glycoimmunology fields are quickly evolving due to the rapid increase in the understanding of the roles played by glycans in immunology, as well as dramatic advances in glycan analytics and the engineering of cellular glycosylation.
Recent studies demonstrate that glycans play predominant roles in immune regulation and cell functions, beyond being structural and folding factors. Glycans enable unique functions by engaging different carbohydrate-binding receptors to induce diverse pathways including modulating immune cells, triggering endocytosis and signalling. Hence, glycan-receptor interaction can be exploited to develop therapeutics with novel modes of action, opening a new front in combating diseases.
Examples of glycan-mediated modes of action enabled by GlycoEra’s Custom Glycan Platform
GlycoEra employs in-depth knowledge of engineering complex carbohydrate structures in vivo and is at the forefront of developing novel glycoengineered therapeutics. GlycoEra’s CustomGlycan Platform is the only cell-based technology offering unparalleled, controlled glycan structure design capabilities, enabling several glycan-mediated functions. This opens a new era in developing novel drugs.